To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy.
INTRODUCTION
Renal cell carcinoma (RCC) is characterized by a high degree of resistance to chemotherapy [1] [2] [3] [4] [5] . Interferon alfa and interleukin-2 are standard therapies for patients with metastatic RCC. Both achieve complete plus partial responses in 10% to 20% of patients [1] [2] [3] [4] [5] . Two randomized trials have shown a survival benefit for interferon alfa [6, 7] , and high-dose interleukin-2 achieved a durable complete response in a subset of highly selected patients [8] . However, only a minority of treated patients experience a favorable response, and few achieve long-term survival. Therefore, the identification of new agents with antitumor activity against RCC is of high priority [9] .
Clinical trials of new agents or cytokine combinations are undertaken in patients as first-line therapy or in previously treated patients after progression to cytokine therapy (cytokine-resistant patients). In each setting, determination of prognostic survival factors in patients with metastatic RCC is important in designing and interpreting the results of phase II and III clinical trials. In particular, phase III clinical trials that include survival as an end point must account for prognostic factors to ensure that treat-ment groups are comparable so that the proper interpretation of trial outcome can be determined. In addition, an accurate assessment of patient survival benefits both patient and physician in clinical management.
Recently, several reports have outlined survival, prognostic factors, and predictive models to treatment with cytokines as first-line therapy (see review in [10, 11] ). These data are being used in designing phase II and III clinical trials and interpreting results. A model derived from Memorial Sloan-Kettering Cancer Center (MSKCC) was based on a study of 670 patients treated during clinical trials between 1975 and 1996 [12] . Five variables were selected by univariate and multivariate analysis as prognostic, and were used as risk factors for short survival: low Karnofsky performance status (Ͻ 80%), high lactate dehydrogenase (Ͼ 1.5 ϫ upper limit of normal), low serum hemoglobin (less than the lower limit of normal), high corrected serum calcium (Ͼ 10 mg/dL), and absence of prior nephrectomy [12] . We also found that survival improved for patients treated in the 1990s compared with patients treated in earlier years [12] . A subsequent analysis was performed in 463 patients treated with interferon alfa as first-line systemic therapy, and the model remained the same except time from diagnosis to treatment with interferon alfa of less than 1 year was found to be a better predictor of short survival compared with the absence of prior nephrectomy [13] .
Data are lacking for survival and predictive features in previously treated patients with metastatic RCC who are entered onto clinical trials. Therefore, we performed a retrospective analysis to identify prognostic factors for survival in previously treated patients with advanced RCC. The patients included in this retrospective series were treated during clinical trials of new agents given as salvage therapy at MSKCC. Because the prior study showed survival was dependent on year of treatment [12] and the purpose of this analysis was to establish prognostic factors for present-day clinical trial design, the univariate survival analysis was performed on patients treated after 1990. The data from this analysis can be applied to clinical trial design and interpretation of new drugs studied as salvage therapy for patients with advanced RCC.
PATIENTS AND METHODS

Patients
All patients were treated on consecutive MSKCC Institutional Review Board-approved clinical trials conducted between September 1975 and November 2002. The trials were identified through eligibility allowing for prior systemic therapy, and patients were selected for this analysis only if they had received systemic therapy for metastases before entry onto the clinical trial. The specific eligibility and treatment programs for these clinical trials have been described previously ( Eligibility details for each trial are described in individual reports. All included informed consent; histologic confirmation of RCC; stage IV disease with presence of measurable lesion(s); adequate Karnofsky performance status; lack of severe comorbid conditions; and adequate hematologic, renal, and hepatic function.
Pretreatment patient characteristics, first date of treatment on the clinical trial, best response, date of progression, and date of death or last follow-up were recorded for all patients. The majority of patients had computed tomography scan of the abdomen and chest to assess extent of disease. Response and progression were defined by WHO criteria for all trials except the last, which used the Response Evaluation Criteria in Solid Tumors Group (RE-CIST) criteria [39] .
Survival Analysis
The end point of interest was survival time, defined as the time from treatment initiation with salvage therapy to the date of death or date of last follow-up. The primary analysis of prognostic factors focused on those patients who had received salvage therapy during or after 1990. Clinical features examined included number and sites of metastases (lung, mediastinum, bone, liver, or retroperitoneum), Karnofsky performance status (Ͻ 80% v Ն 80%), prior nephrectomy, the time interval from diagnosis to start of salvage treatment, and selected baseline biochemical features, including hemoglobin, serum albumin, alkaline phosphatase, lactate dehydrogenase, and total calcium concentrations, on the basis of a previous analysis [12] . To separate out the effects of protein binding and assess free calcium, an adjustment formula was used: corrected calcium ϭ total calcium -0.707 (albumin Ϫ 3.4) [40] . The corrected calcium value was used in the survival analyses.
Survival distributions were estimated using Kaplan-Meier methodology [41] . The relationship between survival and each of the variables was analyzed using the log-rank test [42] for categoric variables and a test score based on the Cox proportional hazards model [43] for continuous variables. There were few missing values for any of the variables (none were Ͼ 2% for all but lactate dehydrogenase concentration, which was missing in 6%), and in all analyses, patient case deletion was used to handle the missing values. When necessary, a logarithmic transformation was used to reduce skewness.
A significant relationship with survival (P Յ .15) was used as the criterion for including a variable in the multivariate stepwise modeling procedure. In the stepwise procedure, a 0.15 significance level for entering and removing explanatory variables was used to determine the independent risk factors. The final model was chosen on the basis of those variables for which P Յ .05. A bootstrap technique [44] confirmed the choice of variables. In the bootstrap technique, 300 bootstrap samples were created and a stepwise procedure was applied to each sample using 0.15 as the significance level for entering and removing a variable. The percentage of samples for which each variable was included in the model from the 300 samples was calculated.
The categoric counterparts of the risk factors determined in the model were used to assign each patient to one of three risk groups: those with zero risk factors (favorable risk), those with one risk factor (intermediate risk), and those with two or more risk factors (poor risk). Survival curves for each of these groups were then estimated (one curve per group). In addition, using these final risk factors, each patient who received salvage therapy before 1990 was then assigned to one of the three risk groups. Survival curves for each group of patients were estimated and compared to those of the patients treated in the later era.
Progression-free survival, defined as the time from treatment initiation with salvage therapy to progression or death, was also examined.
RESULTS
Patient Characteristics
The median age for the 251 patients was 57 years; 67% were male (Table 2) . Seventy-six percent had undergone a nephrectomy and 72% had two or more sites of metastases. Thirty-two percent had received prior radiation therapy; 50% had received interleukin-2 and/or interferon alfa as prior systemic therapy.
The proportion of patients with Karnofsky performance status Ն 80% was higher in patients treated during or after 1990 (81%) compared with patients treated in earlier years (51%). The median hemoglobin level was lower in patients treated before 1990 (11.5 v 12.4 g/dL). The proportion of patients previously treated with interferon alfa and/or interleukin-2 was higher for patients treated with salvage therapy during or after 1990 (80%) when compared with patients treated in earlier years (14%). Conversely, the proportion of patients treated with radiation therapy was less (20% v 46%). A survey of patients treated during or after 1990 showed that 121 (88%) of 137 patients had been treated previously with one prior regimen, 14 patients had received two prior regimens, and two patients had three or four prior regimens.
The overall response rate for the 251 patients was 4%; there were 10 partial responses and no complete responses. Histology was reviewed for 90 patients treated in the later years; 83 had clear-cell, two had chromophobe, three had papillary, and two had collecting-duct carcinoma.
Survival Distribution
The median survival for the 251 patients was 10.2 months (95% CI, 8 to 12). The median survival differed according to year of treatment, with patients treated during or after 1990 showing longer survival (Fig 1) . In this later group, the median overall survival time was 12.7 months (95% CI, 9.8 to 15.3). Twenty-four of the 137 patients remain alive, and the median follow-up time for survivors was 14.7 months (range, 2.1 to 64.9 months). The proportion of patients surviving at 1 year was 52%; the 2-and 3-year survival proportions were 24% and 14%, respectively.
Univariate Survival Analysis
The univariate survival analysis was performed in patients treated in or after 1990 because the goal was to describe this population of patients in the context of presentday clinical trials of new agents. Factors considered in the univariate analyses were based on our prior study, and included number and site of metastasis(es), prior therapy, time from diagnosis to salvage treatment, Karnofsky performance status, and baseline biochemical parameters (Tables  3 and 4) . Table 3 shows the association of each of the categoric variables with survival. The two categoric variables associated with an adverse prognosis were presence of liver metastases and low Karnofsky performance status. Neither the status of prior nephrectomy nor prior cytokine therapy influenced patient survival.
The first two columns of Table 4 give parameter estimates and P values for testing the association of each continuous variable with survival. The continuous variables found to be significant for an adverse prognosis included low serum albumin, elevated serum alkaline phosphatase, low hemoglobin, elevated serum lactate dehydrogenase, a high corrected serum calcium level, and a shorter interval from diagnosis to start of salvage therapy. For alkaline phosphatase, lactate dehydrogenase, and interval from diagnosis to treatment, a logarithmic transformation was used to reduce skewness.
Multivariate Analysis
The seven variables included in the multivariate analysis were Karnofsky performance status, liver metastases, alkaline phosphatase, hemoglobin, lactate dehydrogenase, corrected calcium, and the time interval from diagnosis to treatment. Because corrected calcium is a linear combination of levels of albumin and calcium, among these three variables, only corrected calcium was included in the multivariate analysis. Using a significance level of 0.15 for entering and removing a variable in a stepwise analysis, five variables were retained: Karnofsky performance status, hemoglobin, corrected calcium, lactate dehydrogenase, and liver metastases. However, when fitting the final model with these five variables to obtain parameter estimates and SEs, it was noted that lactate dehydrogenase and liver metastases had P values of more than .10. Therefore, lactate dehydrogenase and liver metastases were not included in the final model.
To confirm this decision, a bootstrapping technique was applied. The percent inclusion among the 300 samples created by the bootstrapping technique for Karnofsky performance status, hemoglobin, and corrected calcium were 96%, 93%, and 84%, respectively. The percentage inclusion for each of the other four variables was lower than 65% (range, 33% to 61%). The results of the bootstrap procedure confirmed the variables chosen for the final model. Therefore, the three independent risk factors predicting survival are corrected calcium, hemoglobin, and Karnofsky performance status.
Risk Groups
Low Karnofsky performance status (Ͻ 80%), low serum hemoglobin, and high corrected calcium were identified as risk factors. Corrected calcium and hemoglobin were dichotomized using previously defined cut-points (corrected calcium, Ͻ 10 v Ն 10 mg/dL; hemoglobin, Յ 13 v Ͼ 13 g/dL for males and Յ 11.5 v Ͼ 11.5 g/dL for females [45] ), and the univariate association of these dichotomized variables with survival is given in the right side of Table 4 . A multivariate Cox model was then fit using the categoric forms of the variables (Table 5) . Each patient was then assigned to one of three risk groups: those with zero risk factors (favorable risk), those with one risk factor (intermediate risk), and those with two or three risk factors (poor risk).
The median time to death in the 42% of patients deemed to be in the favorable-risk group was 22.1 months and the 1-, 2-, and 3-year survival rates were 76%, 42%, and 25%, respectively. Thirty-five percent of the patients were in the intermediate-risk group. The median survival time for this group was 12 months, with 1-, 2-, and 3-year survival rates of 49%, 20%, and 11%, respectively. In contrast, the poor-risk group, which comprised 23% of the patients, had a median survival time of 5 months, with 1-, 2-, and 3-year survival rates of 11%, 0%, and 0%, respectively. There was a significant difference in the survival profiles of the three risk groups (P Ͻ .0001; Fig 2) .
Application of Model to Patients Treated Before 1990
We assigned each of the patients treated before 1990 to one of the three risk groups on the basis of their levels of corrected calcium, serum hemoglobin, and Karnofsky per- formance status (Table 6 ). The proportion of patients assigned to the favorable-risk group (zero risk factors) was 26%, and the proportion of patients assigned to the intermediate category (one risk factor) was 28%. When compared with patients treated 1990 or later (and from whom a model was derived), a greater proportion of patients treated before 1990 were assigned to the poor-risk group (45% in the earlier era v 23% in the later era). This is because the median hemoglobin level is lower in the patients treated in the earlier era than in those from the later era (11.5 v 12.4 g/dL), and 49% of the patients from the earlier era have a Karnofsky performance status less than 80%, in contrast to 16% of the patients treated in the later era.
The survival curves were then estimated for each of the three risk groups (Fig 3) . To examine the equality of the survival outcome for patients in the earlier versus later era after adjusting for risk group, we fit a Cox model with three categories of risk (good v intermediate v poor) and year of treatment (earlier v later era). As expected, risk group is significant (P ϭ .03 and P Ͻ .0001 for favorable v intermediate and favorable v poor, respectively). However, year of treatment is not significant (P ϭ .4), suggesting no difference in survival profile between those treated in the earlier era and those treated in the later era.
Progression-Free Survival Distribution
The median progression-free survival for the 251 patients was 2.4 months (95% CI, 1.9 to 2.9). The median progression-free survival differed according to year of treatment, with patients treated during or after 1990 showing longer progression-free survival, although median progression-free survivals only differed by 1 month (1.9 months for patients treated before 1990 v 2.9 months for patients treated during or after 1990). In the group treated during or after 1990, 14 of 137 patients remain alive and progression free with a median follow-up time of 8.3 months (range, 0.3 to 20.1 months). The proportion of patients that are progression free at 6 months is 26%; the proportion of patients that are progression free at 1 year was 12%.
DISCUSSION
No standard agent or combination program is recognized as effective therapy for patients with metastatic RCC who have experienced disease progression after treatment with interferon alfa or interleukin-2. Second-line treatment with the alternative cytokine is associated with response rates of less than 5% [46] . Two therapies reported to have a low response rate in patients with cytokine-resistant RCC are thalidomide [47, 48] and gemcitabine plus fluorouracil [49] . However, a consensus on the effectiveness of these treatments in producing clinical response is lacking, and there are no randomized trials showing a favorable influence on survival. One study showed that patients with metastatic RCC achieved complete response to allogeneic bone marrow transplantation [50] , but a second study showed that this approach was highly patient selective and toxic [51] . Several new drugs that inhibit angiogenesis show promise from phase I and II trials for producing antitumor effect against metastatic RCC and warrant further study. These include SU11248 [52] , PTK787/ZK222584 [53] , Bevacizumab [54] , and Trap [55] . Patients showing progressive disease after treatment with interferon alfa or interleukin-2 are considered for a clinical trial with a novel agent. The intent of this retrospective analysis was to report on the clinical features and survival of patients comprising this patient population, with information to be used in clinical trial design and interpretation. The median survival for patients treated in recent years with salvage therapy was 12.7 months, and the proportion alive at 2 years was 24%. ‡13 v Ͼ 13g/dL (male) and 11.5 v Ͼ 11.5 g/dL (female). One other report has evaluated survival in 85 previously treated RCC patients receiving salvage therapy during a clinical trial [56] . The median survival was 16 months after second-line therapy [56] . Survival in both studies reflects the natural history of progressive RCC and highlights the need to develop effective systemic therapy. A survey of data for nearly 1,600 patients from three retrospective series of interferon alfa, low-dose interleukin-2, or combination as first-line therapy shows median survivals of 13, 13, and 15 months, respectively [13, 57, 58] . The survival of previously treated patients in our series and by Bou Merhi [56] is longer than might be anticipated by review of survival in the first-line series [13, 57, 58] . The patient population in both the first-line and salvage trials was selected by fulfilling individual protocol eligibility criteria including adequate performance status and baseline laboratory parameters for hematologic, hepatic, and renal function, and lack of comorbid conditions. In addition, some patients with progressive RCC treated with first-line cytokine therapy experienced rapid progression associated with declining clinical status or death [57] . These patients would not be included in the population receiving secondline therapy. Therefore, clinical trials of second-line therapy select some patients with more slowly progressive disease.
Similar clinical features were examined for prognostic importance by univariate and multivariate analyses and compared with those previously reported in patients receiving first-line therapy [13] . All prognostic factors predictive of survival in this series also were found to be predictive in the multivariate analysis from our prior study of patients treated with interferon alfa as first-line therapy [13] . Poor prognostic features found to be significant in the multivariate model and common between the two patient populations were low hemoglobin, high corrected calcium, and low performance status. The two factors that were included in the model for first-line therapy but not in the current series were time from diagnosis to start of cytokine treatment (or prior nephrectomy) and abnormal elevation of serum lactate dehydrogenase. In this study, a relatively high proportion of patients had normal values of lactate dehydrogenase.
The study by Bou Merhi et al [56] also examined prognostic factors for survival and identified three variables that were predictive by multivariate analysis. Two of the three variables predictive in their multivariate analysis [56] were included in our model: low serum hemoglobin and high corrected calcium level. The third, abnormal elevation of serum alkaline phosphatase, was not found to be independently predictive in our analysis. Nevertheless, both analyses represent similar efforts to predict survival and identify prognostic factors in patients with metastatic RCC who are candidates for clinical trials of new agents as second-line therapy. Survival was longer for patients treated in more recent years (in the 1990s) compared with that of patients treated in earlier years. When patients were categorized by risk, survival was similar between the two treatment eras, particularly for poor-and intermediate-risk patients. The median survival was lower for favorable-risk patients treated in the earlier years, but not statistically different from that of favorable-risk patients treated in the 1990s. According to the predictive model, there was a higher proportion of patients with poor-risk features and a lower proportion of patients with favorable-risk features treated in the earlier era. Factors that may be responsible for the lower proportion of patients with poor-risk features in more recent years include improved diagnostic imaging techniques to detect smaller metastases, and selection and referral of patients for clinical trials of second-line therapy.
Specification of RCC histology into subtypes was performed on 90 patients from this retrospective series, and showed that 92% of the patients had clear-cell histology. The remainder had chromophobe, papillary, or collectingduct (nonclear) cell types. Review of pathology from 109 patients treated with interferon alfa as first-line systemic treatment also showed 93% had clear-cell histology [59] . We have previously reported that survival of patients with chromophobe tumors was longer compared with those patients with other non-clear-cell histologies [60] . Nonclear-cell histology is present in a relatively small proportion of patients. However, prospective clinical trials should account for RCC histology because non-clear-cell tumors have different survival potential, and may respond differently to treatment compared with clear-cell histology.
Time to progression is considered a therapeutic end point of phase II and III clinical trials of new agents against metastatic RCC, in addition to best response and survival. The median time to progression in the 251 patients was 2.4 months. The majority had response assessed by WHO (bidimensional criteria). Recently, RECIST criteria have been adopted widely. We compared the time to progression by RECIST (unidimensional) versus WHO (bidimensional) criteria in 53 patients with metastatic RCC treated with thalidomide or interferon alfa (mostly given as first-line therapy) [61] . The average time to progression was 9.2 months measured unidimensionally and 6.4 months when assessed bidimensionally [61] . We also found time to progression averaged 4 months longer when the primary tumor was included in the measurements [61] . When considering time to progression as a clinical end point, the presence or absence of primary tumor influences response assessment, and caution must be taken in comparing results of singlearm phase II studies with historical control.
In summary, treatment with novel agents on a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment. Three prognostic factors for predicting survival were identified and used to categorize previously treated patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more. These risk categories can be used in clinical trial design of phase III trials as stratification factors, in interpreting outcome of phase II trials [62] , and in patient counseling.
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